Qihan Biotech, a biotechnology company founded by Dr. Luhan Yang and Dr. George Church, is harnessing multiplex genome ...
Visit to Klang manufacturing facility held in conjunction with 14th SMIIC Technical Committee Week 2025 in Kuala Lumpur -- ...
Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. | Zenas Biopharma’s lead autoimmune drug ...
Interesting Engineering on MSN
‘Masters of disguise’: US team recreates octopus pigments to boost camouflage tech
US scientists have bioengineered the octopus pigment xanthommatin in bacteria, producing 1,000 times more material than ...
VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug ...
The 2025 Prix Galien Africa has honoured Côte d’Ivoire’s La Ruche Health, led by Mr. Rory Assandey, for its groundbreaking ...
News-Medical.Net on MSN
First multiple sclerosis patient in the UK receives CAR T cell therapy in groundbreaking trial
A multiple sclerosis (MS) patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a ...
Eyeing a drug that it believes holds peak annual sales potential of $12 billion in the U.S. alone, Zenas BioPharma has struck a licensing deal with China-based InnoCare Pharma that could be worth more ...
New scientific article warns of loss of consumer trust unless proper analysis is done. Report: Claire Robinson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback